Actinogen ACW0002A

Back to Drug Development Trials
Drug Development Trials

About the trial

A Non-interventional Biomarker Analysis Extension Protocol for Participants Who Were Previously Enrolled in XanADu: A Phase 2, Double-Blind, 12-Week, Randomised, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Xanamem™ in Subjects with Mild Dementia due to Alzheimer’s Disease (AD).

View study